about
Oral Apremilast for the Treatment of Plaque PsoriasisUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm MeetingPharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.Recurrence of Melanoma after Starting Apremilast for Psoriasis.Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis.
P2860
Q28075724-E29E7D64-F7E2-4FFF-AE82-2C7CFDD33840Q35822379-229484A8-026F-4EA7-8E8A-444E86AF695BQ38885459-23B0B226-105B-49BC-B3DA-B11FBAE87995Q42368832-9F04AFC1-BF85-4163-BEAC-79C30B346925Q47877796-1100A21D-B8CD-4EAF-A9C7-EC87FD7B9A29Q50142481-1019CD0B-7280-4A0B-B42B-3C7FE55B6B5FQ54214722-7E6EC920-1845-4AFD-9807-888CAC91C8B1
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Apremilast for the treatment of psoriasis.
@en
type
label
Apremilast for the treatment of psoriasis.
@en
prefLabel
Apremilast for the treatment of psoriasis.
@en
P2093
P2860
P1476
Apremilast for the treatment of psoriasis.
@en
P2093
Andrea Chiricozzi
Luca Bianchi
Oreste Buonomo
Roberto Perricone
Rosita Saraceno
Sergio Chimenti
Talia Gramiccia
Virginia Garofalo
P2860
P304
P356
10.1517/14656566.2015.1076794
P407
P577
2015-08-04T00:00:00Z